Novo Nordisk Stock: Does Oral Wegovy Approval Make It Better Pick Than Eli Lilly?
As physicians prioritize efficacy, oral Wegovy could become the preferred option, giving Novo Nordisk a competitive advantage in capturing market share early.
Great Quarter, Guys
The initial estimate of 4.3% for Q3 Annualized Real GDP was indeed a stunner. It blew past both last quarter’s 3.8% and the consensus estimate of 3.3%.
Canadian Dollar Tests Five-Month Highs On Tuesday
Canadian dollar hits five-month highs, driving USD/CAD to 22-week lows amid broad U.S. Dollar weakness.
Real GDP Has Exceeded GDI For 12 Straight Quarters, What’s Going On?
Let’s discuss the statistical discrepancy.
The $12,000 Signal: This Massive Disconnect Is Fueling A Copper Supercycle
As copper reaches an all time high, here's what the moment really means for investors.